• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Capricor Therapeutics Inc.

    2/5/25 5:20:12 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email
    S-8 1 tmb-20250207xs8.htm S-8

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    Capricor Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

    ​

    Delaware

    88-0363465

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification Number)

    ​

    Capricor Therapeutics, Inc.

    10865 Road to the Cure, Suite 150

    San Diego, CA 92121

    (858) 727-1755

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)


    2021 EQUITY INCENTIVE PLAN

    (Full title of the plan)


    Karen G. Krasney, Esq.

    Capricor Therapeutics, Inc.

    10865 Road to the Cure, Suite 150

    San Diego, CA 92121

    (858) 727-1755

    (Name, address, including zip code, and telephone number, including area code, of agent for service)


    Copies to:

    Robert R. Carlson, Esq.

    Sidley Austin LLP

    1001 Page Mill Road Building 1

    Palo Alto, CA 94304

    Telephone: (650) 565-7000


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

    ​

    Large accelerated filer

    ◻

    Accelerated filer

    ◻

    Non-accelerated filer

    ⌧

    Smaller reporting company

    ⌧

    ​

    ​

    ​

    ​

    ​

    Emerging growth company

    ◻

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

    ​

    ​

    ​


    EXPLANATORY NOTE

    The Registrant has prepared this registration statement (this “Registration Statement”) in accordance with the requirement of Form S-8 under the Securities Act, to register 2,279,114 shares of Common Stock issuable pursuant to the 2021 Plan. The 2021 Plan has been previously approved by the Registrant’s stockholders.

    ​


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation, by reference, or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commissions (the “Commission”).

    ​


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.

    The following documents, which were filed with the Commission, are incorporated herein by reference:

    (a)(1)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 11, 2024, including all material incorporated by reference therein;

    (b)(1)

    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the Commission on May 14, 2024, including all material incorporated by reference therein;

    (b)(2)

    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, filed with the Commission on August 8, 2024, including all material incorporated by reference therein;

    (b)(3)

    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, filed with the Commission on November 14, 2024, including all material incorporated by reference therein;

    (b)(4)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on January 11, 2024, including all material incorporated by reference therein;

    (b)(5)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on May 15, 2024, including all material incorporated by reference therein;

    (b)(6)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on May 15, 2024, including all material incorporated by reference therein;

    (b)(7)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on September 17, 2024 (other than any portions thereof deemed furnished and not filed), including all material incorporated by reference therein;

    (b)(8)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on October 9, 2024 (other than any portions thereof deemed furnished and not filed), including all material incorporated by reference therein;

    (b)(9)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on October 16, 2024 (other than any portions thereof deemed furnished and not filed), including all material incorporated by reference therein;

    (b)(10)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on October 17, 2024 (other than any portions thereof deemed furnished and not filed), including all material incorporated by reference therein.

    (b)(11)

    The Registrant’s Current Report on Form 8-K, filed with the Commission on January 2, 2025, including all material incorporated by reference therein.

    (c)(1)

    The description of the Registrant’s Common Stock contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 11, 2024, including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.


    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

    Item 4.Description of Securities.

    Not applicable.

    Item 5.Interests of Named Experts and Counsel.

    Not applicable.

    Item 6.Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

    The Registrant’s Certificate of Incorporation, as amended (the “Certificate”), requires the Registrant to indemnify its directors and officers to the fullest extent permitted by the DGCL as it presently exists or as may hereafter be amended. Therefore, a director of the Registrant will not be liable to the Registrant or the Registrant’s stockholders for monetary damages for any breach of fiduciary duty as a director, provided that the individual acted in good faith and in a manner the individual reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Registrant’s directors will be further limited to the greatest extent permitted by the DGCL.

    Additionally, the provisions of the Certificate and of the Registrant’s bylaws require the Registrant to indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or as may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Registrant or, while a director or officer of the Registrant, is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such person. Notwithstanding the preceding sentence, the Registrant shall be required to indemnify such a person in connection with a proceeding (or part thereof) commenced by such person only if the commencement of such proceeding (or part thereof) by the person was authorized in the specific case by the Board of Directors. The Registrant’s bylaws also provide that the Registrant shall, to the fullest extent not prohibited by applicable law, promptly pay the expenses, including attorneys’ fees, incurred by a director or officer in defending any proceeding in advance of its final disposition, subject to certain limited exceptions.

    The Registrant’s bylaws permit the Registrant to purchase and maintain insurance on behalf of any person that the Registrant is permitted to indemnify in accordance with the bylaws against any liability asserted again any such person and incurred by such person, whether or not the Registrant would have the power to indemnify such person against such liability under the DGCL. In accordance with the provisions of the bylaws, the Registrant currently maintains directors’ and officers’ liability insurance, which may insure against director or officer liability arising under the Securities Act. In addition, the Registrant has entered into various agreements whereby it has agreed to indemnify its directors and officers for specific liabilities that they may incur while serving in such capacities. These indemnification agreements provide for


    the maximum indemnity allowed to directors and officers by applicable law. The Registrant believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

    The limitation of liability and indemnification provisions that are included in the Certificate, the Registrant’s bylaws and in indemnification agreements that the Registrant enters into with its directors and officers may discourage stockholders from bringing a lawsuit against the Registrant’s directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and officers, even though an action, if successful, might benefit the Registrant and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that the Registrant pays the costs of settlement and damage awards against directors and executive officers as required by the applicable indemnification provisions. At present, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers, employees or other agents or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and the Registrant is not aware of any threatened litigation that may result in claims for indemnification.

    The foregoing statements are subject to the detailed provisions of the DGCL and the full text of the corporate documents and agreements referenced above.

    Reference is made to Item 9 for the Registrant’s undertakings with respect to indemnification for liabilities arising under the Securities Act of 1933, as amended.

    Item 7.Exemption from Registration Claimed.

    Not applicable.


    Item 8.Exhibits.

    ​

    ​

    ​

    4.1

        

    Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 9, 2007).

    ​

    ​

    ​

    4.2

    ​

    Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 26, 2013).

    ​

    ​

    ​

    4.3

    ​

    Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 4, 2019).

    ​

    ​

    ​

    ​

    4.4

    ​

    Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 15, 2024).

    ​

    ​

    ​

    4.5

    ​

    Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on February 9, 2007).

    ​

    ​

    ​

    4.6

    ​

    Certificate of Amendment of the Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 25, 2020).

    ​

    ​

    ​

    4.7

    ​

    Capricor Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2021).

    ​

    ​

    ​

    4.8

    ​

    Form of Stock Option Agreement for Capricor Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2021).

    ​

    ​

    ​

    5.1*

    ​

    Opinion of Sidley Austin LLP.

    ​

    ​

    ​

    23.1*

    ​

    Consent of Rose Snyder & Jacobs, LLP.

    ​

    ​

    ​

    23.2*

    ​

    Consent of Sidley Austin LLP (included in Exhibit 5.1).

    ​

    ​

    ​

    24.1*

    ​

    Power of Attorney (included on signature page hereof).

    ​

    ​

    ​

    107.1*

    ​

    Filing Fee Table.


    *

    Filed herewith.

    ​


    Item 9. Undertakings.

    (a)  The undersigned registrant hereby undertakes:

    (1)  To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)  To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii)  To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

    (iii)  To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided, however, that:

    Paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

    (2)  That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)  The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h)  Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 5, 2025.

    CAPRICOR THERAPEUTICS, INC.

    By:

    /s/ Linda Marbán, Ph.D.

    Linda Marbán, Ph.D.

    Chief Executive Officer

    ​

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Linda Marbán, Ph.D. and Anthony J. Bergmann and each of them singly, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement and additional registration statements relating to the same offering, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes, may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

        

    Title

        

    Date

    /s/ Linda Marbán, Ph.D.

    Chief Executive Officer and Director

    February 5, 2025

    Linda Marbán, Ph.D.

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    /s/ Anthony J. Bergmann

    Chief Financial Officer

    February 5, 2025

    Anthony J. Bergmann

    (Principal Financial Officer and Principal Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    /s/ Frank Litvack, M.D.

    Executive Chairman and Director

    February 5, 2025

    Frank Litvack, M.D.

    ​

    ​

    ​

    ​

    ​

    /s/ Earl M. Collier

    Director

    February 5, 2025

    Earl M. Collier

    ​

    ​

    ​

    ​

    ​

    /s/ David B. Musket

    Director

    February 5, 2025

    David B. Musket

    ​

    ​

    ​

    ​

    ​

    /s/ George W. Dunbar

    Director

    February 5, 2025

    George W. Dunbar

    ​

    ​

    ​

    ​

    ​

    /s/ Karimah Es Sabar

    Director

    February 5, 2025

    Karimah Es Sabar

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Michael Kelliher

    Director

    February 5, 2025

    Michael Kelliher

    ​

    ​

    ​

    ​

    ​

    /s/ Philip J. Gotwals

    Director

    February 5, 2025

    Philip J. Gotwals

    ​

    ​

    ​

    ​

    ​

    /s/ Paul G. Auwaerter

    Director

    February 5, 2025

    Paul G. Auwaerter

    ​


    Get the next $CAPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    10/11/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

      5/13/25 4:05:00 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

      5/13/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      9/24/24 4:01:08 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/13/23 1:59:57 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/12/23 9:15:07 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Financials

    Live finance-specific insights

    See more
    • Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

      5/13/25 4:05:00 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

      SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18

      3/11/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      11/8/24 9:00:23 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      9/24/24 4:03:22 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      8/23/24 4:01:31 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Capricor Therapeutics with a new price target

      Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00

      10/21/24 7:35:33 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Capricor Therapeutics with a new price target

      Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00

      5/17/24 7:29:53 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Capricor Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/5/24 7:28:46 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

      5/13/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

      7/1/24 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

      SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

      9/6/23 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Marban Linda exercised 25,000 shares at a strike of $1.39 and disposed of 12,500 shares, increasing direct ownership by 6% to 211,104 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/5/25 5:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 2,500 shares at a strike of $1.39, increasing direct ownership by 44% to 8,223 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:17 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Litvack Frank exercised 25,000 shares at a strike of $1.39 and covered exercise/tax liability with 2,543 shares, increasing direct ownership by 21% to 129,839 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Capricor Therapeutics Inc.

      10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/14/25 4:30:49 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/13/25 4:06:28 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

      SCHEDULE 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      4/30/25 10:58:05 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care